BreStem Therapeutics

BreStem Therapeutics is pioneering lung regeneration therapies from its base in San Diego. The company's core innovation is the isolation and expansion of intrinsic lung spheroid cells (LSCs), with its lead autologous candidate BRS101 cleared for clinical trials in idiopathic pulmonary fibrosis. With a second, cell-free exosome program in preIND development and a founding team led by a renowned academic researcher, BreStem aims to address a high-mortality market with significant unmet need. The company is privately held and appears to be in a pre-revenue, clinical-stage development phase.

Proprietary platform for isolating and expanding Lung Spheroid Cells (LSCs) from a patient's own tissue, with extensions into cell-free secretome/exosome production and nanotechnology for delivery.

Competes against approved anti-fibrotic drugs (e.g., pirfenidone, nintedanib) that slow decline, and the standard of lung transplantation. Other biotechs are developing novel anti-fibrotics and cell therapies, but BreStem's focus on intrinsic lung stem cells is a differentiated approach.